Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 112

1.
2.
3.

Moderate dietary sodium restriction added to angiotensin converting enzyme inhibition compared with dual blockade in lowering proteinuria and blood pressure: randomised controlled trial.

Slagman MC, Waanders F, Hemmelder MH, Woittiez AJ, Janssen WM, Lambers Heerspink HJ, Navis G, Laverman GD; HOlland NEphrology STudy Group.

BMJ. 2011 Jul 26;343:d4366. doi: 10.1136/bmj.d4366.

4.

Effects of an ACE inhibitor/calcium antagonist combination on proteinuria in diabetic nephropathy.

Bakris GL, Weir MR, DeQuattro V, McMahon FG.

Kidney Int. 1998 Oct;54(4):1283-9.

6.

Evidence of a threshold value of glycated hemoglobin to improve the course of renal function in type 2 diabetes with typical diabetic glomerulopathy.

Brocco E, Velussi M, Cernigoi AM, Abaterusso C, Bruseghin M, Carraro A, Sambataro M, Piarulli F, Sfriso A, Nosadini R.

J Nephrol. 2001 Nov-Dec;14(6):461-71.

PMID:
11783602
7.
9.

The effects of metformin on glycemic control and serum lipids in insulin-treated NIDDM patients with suboptimal metabolic control.

Robinson AC, Burke J, Robinson S, Johnston DG, Elkeles RS.

Diabetes Care. 1998 May;21(5):701-5.

PMID:
9589227
10.

Effect of pioglitazone and acarbose on endothelial inflammation biomarkers during oral glucose tolerance test in diabetic patients treated with sulphonylureas and metformin.

Derosa G, Mereu R, D'Angelo A, Salvadeo SA, Ferrari I, Fogari E, Gravina A, Palumbo I, Maffioli P, Randazzo S, Cicero AF.

J Clin Pharm Ther. 2010 Oct;35(5):565-79. doi: 10.1111/j.1365-2710.2009.01132.x.

PMID:
20831680
11.
12.

A primary care register for impaired glucose handling (IGH): impact on cardiometabolic profile.

Heald AH, Knapman H, Nair S, Chambers T, Radford D, Rushton T, Anderson SG.

Prim Care Diabetes. 2012 Oct;6(3):213-9. doi: 10.1016/j.pcd.2012.02.002. Epub 2012 May 4.

PMID:
22560663
13.

Impact of metformin versus the prandial insulin secretagogue, repaglinide, on fasting and postprandial glucose and lipid responses in non-obese patients with type 2 diabetes.

Lund SS, Tarnow L, Frandsen M, Smidt UM, Pedersen O, Parving HH, Vaag AA.

Eur J Endocrinol. 2008 Jan;158(1):35-46. doi: 10.1530/EJE-07-0500. Erratum in: Eur J Endocrinol. 2011 Nov;165(5):831.

14.

Effects of antihyperglycaemic therapies on proinsulin and relation between proinsulin and cardiovascular risk factors in type 2 diabetes.

Hermann LS, Ranstam J, Vaaler S, Melander A.

Diabetes Obes Metab. 1999 Jul;1(4):227-32.

PMID:
11228758
15.

The short-term effect of a switch from glibenclamide to metformin on blood pressure and microalbuminuria in patients with type 2 diabetes mellitus.

Amador-Licona N, Guízar-Mendoza J, Vargas E, Sánchez-Camargo G, Zamora-Mata L.

Arch Med Res. 2000 Nov-Dec;31(6):571-5.

PMID:
11257323
16.

Relationship between ethnicity and glycemic control, lipid profiles, and blood pressure during the first 9 years of type 2 diabetes: U.K. Prospective Diabetes Study (UKPDS 55).

Davis TM, Cull CA, Holman RR; U.K. Prospective Diabetes Study (UKPDS) Group.

Diabetes Care. 2001 Jul;24(7):1167-74.

PMID:
11423497
17.

[Risk and prevention of diabetic nephropathy].

Ravera M, Re M, Deferrari G.

G Ital Nefrol. 2007 Sep-Oct;24 Suppl 38:13-9. Italian.

PMID:
17922442
18.

Effects of acarbose versus glibenclamide on glycemic excursion and oxidative stress in type 2 diabetic patients inadequately controlled by metformin: a 24-week, randomized, open-label, parallel-group comparison.

Wang JS, Lin SD, Lee WJ, Su SL, Lee IT, Tu ST, Tseng YH, Lin SY, Sheu WH.

Clin Ther. 2011 Dec;33(12):1932-42. doi: 10.1016/j.clinthera.2011.10.014. Epub 2011 Nov 10.

PMID:
22078152
19.

Nateglinide and glibenclamide metabolic effects in naïve type 2 diabetic patients treated with metformin.

Derosa G, D'Angelo A, Fogari E, Salvadeo S, Gravina A, Ferrari I, Cicero AF.

J Clin Pharm Ther. 2009 Feb;34(1):13-23. doi: 10.1111/j.1365-2710.2008.00984.x.

PMID:
19125899
20.

Renal and metabolic effects of 1-year treatment with ramipril or atenolol in NIDDM patients with microalbuminuria.

Schnack C, Hoffmann W, Hopmeier P, Schernthaner G.

Diabetologia. 1996 Dec;39(12):1611-6.

PMID:
8960851

Supplemental Content

Support Center